PROBLEM TO BE SOLVED: To provide a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis.SOLUTION: In the use of Cladribine for the preparation of a pharmaceutical formulation, a Cladribine pharmaceutical formulation is orally administered according to the following successive steps: (i) an induction period in which the Cladribine pharmaceutical formulation is administered with the total dosage of Cladribine at the end of the induction period being 1.7 mg/kg to about 3.5 mg/kg (ii) a non-Cladribine period in which no Cladribine is administered (iii) a maintenance period in which the Cladribine pharmaceutical formulation is administered with the total dosage of Cladribine at the end of the maintenance period being smaller than the total dosage of Cladribine at the end of induction period (i) or about 1.7 mg/kg and (iv) a non-Cladribine period in which no Cladribine is administered.COPYRIGHT: (C)2014,JPO&INPIT【課題】多発性硬化症の治療用製剤の提供。【解決手段】以下の逐次ステップ:(i)誘導期、ここでは、クラドリビン医薬製剤が投与され、且つ、当該誘導期の終了時点で到達するクラドリビンの総用量が約1.7mg/kg~約3.5mg/kgであり;(ii)無クラドリビン期、ここでは、クラドリビンが全く投与されず;(iii)維持期、ここでは、クラドリビン医薬製剤が投与され、且つ、当該維持期の終了時点で到達するクラドリビンの総用量が上記誘導期(i)の終了時点で到達するクラドリビンの総用量より少なく、又は約1.7mg/kgであり;(iv)無クラドリビン期、ここでは、クラドリビンが全く投与されない、に従って経口投与される、医薬製剤の製造のためのクラドリビンの使用【選択図】なし
